4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. (FDMT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
fdmt · stock forecast · 14 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 14 Wall Street analysts in the past 3 months
Buy
14 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$33.00
Consensus
$33.00
+281.9% upside
Low
$33.00
Median: $33 · Last Close: $8.64
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $8.70 | ↑ 0.74% |
1-day model range: $8.62–$8.78. Peak: $8.78 (+0.74%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · FDMT · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-20 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-03-19 | Chardan Capital | Maintains | Buy→Buy |
| 2026-03-19 | RBC Capital | Maintains | Outperform→Outperform |
| 2025-12-18 | Chardan Capital | Maintains | Buy→Buy |
| 2025-11-11 | Chardan Capital | Maintains | Buy→Buy |
| 2025-11-11 | Barclays | Maintains | Overweight→Overweight |
| 2025-11-11 | RBC Capital | Maintains | Outperform→Outperform |
| 2025-10-21 | RBC Capital | Maintains | Outperform→Outperform |
| 2025-08-12 | Roth Capital | Maintains | Buy→Buy |
| 2025-08-12 | Chardan Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on 4D Molecular Therapeutics, Inc. (FDMT) stock. Of the recent 70 rating actions, 1 were upgrades and 2 were downgrades. 14 analysts currently cover FDMT.
Analyst Recommendation Trends
FDMT analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 3 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$11M
↓ 73.8% YoY
Revenue Next Year
$15M
↑ 39.6% YoY
EPS This Year
$-3.89
EPS Next Year
$-3.72
↓ 4.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast FDMT EPS of $-3.89 for the current fiscal year, based on estimates from 5 analysts. The FDMT revenue forecast is $11M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The FDMT stock forecast is supported by two independent data sources: analyst consensus ratings from 14 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus FDMT price target is $33.00 (+281.9% upside), with an analyst consensus of Buy.
The FDMT short-term stock prediction for tomorrow is $8.70 (+0.74%).
4D Molecular Therapeutics, Inc. trades on NASDAQ under the ticker FDMT. The FDMT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 71% of covering analysts.
Frequently asked questions
FDMT forecast · 8 questionsAccording to 14 Wall Street analysts, the average 12-month FDMT price target is $33.00, with a high forecast of $33.00 and a low of $33.00. The median price target is shown in the chart above when available. This implies +281.9% potential upside from the current price of $8.64.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.